Celyad to Host Remote 2020 Ordinary General Meeting
April 22, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, April 22, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Reports Full Year 2019 Financial Results and Provides Business Update
March 24, 2020 19:22 ET
|
Celyad SA
First patient successfully dosed in expansion cohort of autologous CYAD-01 THINK trial for patients with relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes...
Celyad to Announce Full Year 2019 Financial Results and Host Conference Call
March 12, 2020 16:01 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 12, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Appoints Stephen Rubino as Chief Business Officer
March 02, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, March 02, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces February and March 2020 Conference Schedule
February 17, 2020 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Feb. 17, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS
January 13, 2020 01:00 ET
|
Celyad SA
Preliminary data from the Phase 1 CYCLE-1 trial are expected during second half 2020 MONT-SAINT-GUIBERT, Belgium, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq:...
Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting
December 09, 2019 18:30 ET
|
Celyad SA
Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing processEnrollment of...
Celyad Receives Additional €2.5 Million in Non-Dilutive Funding
December 06, 2019 01:00 ET
|
Celyad SA
MONT-SAINT-GUIBERT, Belgium, Dec. 06, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T...
Celyad Announces Board of Directors Evolution with New Appointment
November 29, 2019 01:00 ET
|
Celyad SA
Dr. Christian Homsy steps down from the Celyad Board of Directors as current CEO Filippo Petti is nominated into the role MONT-SAINT-GUIBERT, Belgium, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Celyad...
Celyad Receives €8.5 Million in Grants and Non-Dilutive Funding by the Walloon Region
November 22, 2019 01:00 ET
|
Celyad SA
Funding will support the advancement of the Company’s autologous and allogeneic CAR-T cell therapy programs MONT-SAINT-GUIBERT, Belgium, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels...